Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II TVD regimen in children with stage 4 neuroblastoma refractory to COJEC
2005-000915-80Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan, vincristine and doxorubicin in neuroblastoma, sponsored by University of Birmingham. Primary endpoint: Objective response rate after two cycles of TVD. Started Aug 2005; status: completed.
02
Drugs
topotecanvincristinedoxorubicin
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2005-000915-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000915-80.